Novo Nordisk has decided to reduce the number of its executives from seven to six resulting in the departure of its chief of staffs Lise Kingo.
Kingo’s responsibilities will be split among the remaining executives, including Lars Fruergaard Jørgensen, Jakob Riis and CEO Lars Rebien Sørensen.
Sørensen said: “I would like to thank Lise for her many contributions to Novo Nordisk during her impressive career in the company. Of special note is her leadership in driving the company’s strategy within sustainable development, corporate branding and public affairs, which has earned Novo Nordisk recognition as a respected global business.”
Kingo joined Novo in 1988 and worked her way up the ranks, being appointed senior VP in 1999 and then as executive VP and chief of staffs in 2002. Her other roles include chair of the board of Steno Diabetes Center and member of the board of Grieg Star Group.